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Abstract
Background: The majority of investigations on HIV-associated neurocognitive disorders (HAND) neglect the
cerebellum in spite of emerging evidence for its role in higher cognitive functions and dysfunctions in common
neurodegenerative diseases.
Methods: We systematically investigated the molecular and cellular responses of the cerebellum as contributors to
lentiviral infection-induced neurodegeneration, in the simian immunodeficiency virus (SIV)-infected rhesus macaque
model for HIV infection and HAND. Four cohorts of animals were studied: non-infected controls, SIV-infected
asymptomatic animals, and SIV-infected AIDS-diseased animals with and without brain-permeant antiretroviral
treatment. The antiretroviral utilized was 6-chloro-2′,3′-dideoxyguanosine (6-Cl-ddG), a CNS-permeable nucleoside
reverse transcriptase inhibitor. Quantitation of granule cells and Purkinje cells, of an established biomarker of SIV
infection (gp41), of microglial/monocyte/macrophage markers (IBA-1, CD68, CD163), and of the astroglial marker
(GFAP) were used to reveal cell-specific cerebellar responses to lentiviral infection and antiretroviral therapy (ART).
The macromolecular integrity of the blood brain barrier was tested by albumin immunohistochemistry.
Results: Productive CNS infection was observed in the symptomatic stage of disease, and correlated with extensive
microglial/macrophage and astrocyte activation, and widespread macromolecular blood brain barrier defects. Signs
of productive infection, and inflammation, were reversed upon treatment with 6-Cl-ddG, except for a residual low-
grade activation of microglial cells and astrocytes. There was an extensive loss of granule cells in the SIV-infected
asymptomatic cohort, which was further increased in the symptomatic stage of the disease and persisted after 6-Cl-
ddG (administered after the onset of symptoms of AIDS). In the symptomatic stage, Purkinje cell density was
reduced. Purkinje cell loss was likewise unaffected by 6-Cl-ddG treatment at this time.
Conclusions: Our findings suggest that neurodegenerative mechanisms are triggered by SIV infection early in the
disease process, i. e., preceding large-scale cerebellar productive infection and marked neuroinflammation. These
affect primarily granule cells early in disease, with later involvement of Purkinje cells, indicating differential
vulnerability of the two neuronal populations. The results presented here indicate a role for the cerebellum in
neuro-AIDS. They also support the conclusion that, in order to attenuate the development of motor and cognitive
dysfunctions in HIV-positive individuals, CNS-permeant antiretroviral therapy combined with anti-inflammatory and
neuroprotective treatment is indicated even before overt signs of CNS inflammation occur.
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Background
More than three decades after the discovery of the
human immunodeficiency virus (HIV), HIV infections
and their consequences remain a major global health
concern. Modern antiretroviral therapy (ART) durably
suppresses viral replication, improves immune function,
and halts clinical disease progression, yet the prevalence
of neurological disorders remains persistently high in HIV
+ individuals [1]. These variegated neurological complica-
tions are grouped under the term HIV-associated neuro-
cognitive disorders (HAND). Clinical features of HAND
include cognitive deficits in attention, memory, executive
function, and informational processing and also particu-
larly cerebellum-associated motor symptoms including
gait disturbance, limb weakness, and tremor [2–4]. In-
fected individuals also frequently exhibit severe affective
disturbances early in the course of disease [5, 6]. The
nosology for HAND delineates three levels of severity:
HIV-associated asymptomatic neurocognitive impairment
(ANI), HIV-associated mild neurocognitive disorders
(MND), and HIV-associated dementia (HAD) [7]. While
the most severe manifestation of HAND (HAD) is rare in
the era of ART, the prevalence of cognitive deficits overall
remains high, even among aviremic patients [1, 8, 9]. ANI
and MND significantly interfere with activities of daily life
(e. g., employment, medication management, etc.) and are
associated with an increased risk for early development of
symptomatic HAND and even increased mortality com-
pared with neuropsychologically unimpaired HIV+ indi-
viduals [10–13]. According to widely recognized theories,
neuronal damage is mainly caused by the virus-dependent
activation of macrophages and microglia. This alters the
production of chemokines and cytokines and leads to a
dysregulation of immune functions and production of
neurotoxic substances and harmful viral proteins in the
brain [14–18]. Previous neuropathological studies of HIV
infection focused mainly on neocortical brain areas trad-
itionally associated with higher cognitive functions, in-
cluding frontal, prefrontal, parietal, and temporal cortices
and basal ganglia [19–22]. However, there is also emerging
evidence for a role of the cerebellum in higher cognitive
functions and more recently for an involvement in
HAND [23]. In fact, the observation that the cerebellar
dentate nucleus is expanded in anthropoid apes and
humans in parallel with the prefrontal cortex relative to
other species has laid foundations for subsequent inves-
tigations revealing an emerging role of the cerebellum
in many non-motor as well as motor functions [24].
Thus, a multitude of functional imaging and anatomical
and clinical studies support the participation of the
cerebellum in cognitive functions such as language,
visual-spatial, executive, and working-memory pro-
cesses [25–28]. Schmahmann and Sherman have pro-
mulgated a distinct term for disturbances related to
cerebellar damage— the cerebellar cognitive affective syn-
drome (CCAS) [29]. Comparing the symptoms of CCAS
and HAND, there is striking congruency. Unexplained
cerebellar atrophy has been found with neuroimaging in
HIV patients indicating that neurodegeneration in the
cerebellum occurs as a consequence of HIV infection [30].
However, it is unexplored which type of cerebellar neu-
rons degenerate and to what extent neuronal cerebellar
degeneration is related to neuroinflammatory events
within the cerebellum [31].
Considering this background, the present study system-
atically investigates for the first time the molecular and
cellular patterns of the cerebellar response to lentiviral in-
fection, and the consequences of antiretroviral treatment,
in a primate model of HIV infection, the simian immuno-
deficiency virus (SIV)-infected rhesus macaque.
Methods
Virus stock, inoculation procedures, antiretroviral
treatment
All experiments involving the use of rhesus macaques
were approved by the Animal Care and Use Committee
of Bioqual, Inc., and were carried out under the ethical
guidelines in the NIH Guide for the Care and Use of
Laboratory Animals and adhere to the ARRIVE guide-
lines. In brief, healthy juvenile male rhesus macaques
were inoculated intravenously with ten rhesus infec-
tious doses of cell-free human peripheral blood mono-
nuclear cell (hPBMC)-grown SIV strain deltaB670 and
then monitored and examined for clinical evidence of dis-
ease [32]. At the time of death, seven animals exhibited
clinical signs of AIDS (SIV/+AIDS) and five did not (SIV/-
AIDS). Four age-matched non-infected macaques served
as controls (Ctrl). In addition, six SIV-infected macaques
were treated with 6-chloro-2′,3′-dideoxyguanosine (6-Cl-
ddG) when they exhibited clinical signs of AIDS, coinci-
dent with a viral load greater than 100,000 virions/mL in
plasma and greater than 100 virions/mL in CSF (SIV/
+AIDS/+ddG) [32]. Initially, five macaques received daily
10 mg/kg subcutaneously of 2′,3′-dideoxyinosine for
3 weeks for clinical stabilization and then 75 mg/kg per
day of 6-Cl-ddG for 6 weeks. Only one macaque was
treated daily with 6-Cl-ddG alone (75 mg/kg) for 3 weeks.
Table 1 shows the infection status, treatment regime, and
clinical status of the macaques used in the present study.
Tissue preparation, histological staining
At the time of death, the macaques were anesthetized
with ketamine and transcardially perfused with PBS and
formalin/PBS. Tissue specimens were obtained during
necropsy, immersion-fixed overnight, and then post-
fixed with Bouin-Hollande solution and processed for
paraffin embedding. All cerebellar tissue samples were
cut into 7-μm-thick sections using a Thermo Scientific
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HM 325 rotary microtome. Giemsa staining was per-
formed with Giemsa staining solution (Merck, Darmstadt,
Germany). Differentiation of red shades was done with
acetic acid and of blue shades with isopropanol 70 %.
Sections were covered with Eukitt mounting medium
(Sigma-Aldrich, Schnelldorf, Germany).
Immunohistochemistry
In brief, cerebellar tissue sections were deparaffinized,
incubated in citrate buffer (pH 6.0) at 92–95 °C for
10 min [32, 33], subsequently permeabilized and
blocked for non-specific binding using the Vecta-Lab
avidin/biotin blocking kit (Vector Laboratories, Burlin-
game, USA), and incubated with primary antibodies.
Immunolabeling was performed using fluorochrome-
conjugated secondary antibodies (1:200; Dianova) or,
alternatively, biotinylated secondary antibodies (1:200;
Dianova, Hamburg, Germany), standard avidin-biotin-
peroxidase technique (1:500; Vectastain Elite ABC kit,
Vector Laboratories), and 3,3′-diaminobenzidine (Sigma,
Deisenhofen, Germany) with ammonium nickel sulfate
(Fluka, Buchs, Switzerland), resulting in dark blue/black
staining. For the visualization of two antigens in the same
section, double immunostaining was performed. The pri-
mary antibodies used are anti-albumin (rabbit, 1:20.000,
Cat No A001, DAKO, Hamburg, Germany), anti-CD68
(mouse, 1:1.000, Cat No M0876, DAKO, Hamburg,
Germany), anti-CD163 (mouse, 1:2.000, Cat No MCA1853,
AbD Serotec, Puchheim, Germany), anti-GFAP (guinea pig,
1:4.000, Cat No GP52, Progen, Heidelberg, Germany),
anti-IBA-1 (rabbit, 1:3.000, Cat No 019–19741, WAKO
Chemicals, Neuss, Germany), and SIVmac251 gp41
(mouse, 1:4.000, National Institute of Health, AIDS
Research and Reference Program, Germantown, USA).
Immunostained sections were analyzed and documented
with Olympus AX70 (Olympus Optical, Hamburg,
Germany) or Zeiss Axio Imager.M2 (Zeiss, Oberkochen,
Germany) microscopes.
Quantitative image analysis
To achieve an unbiased analysis of immunohistochemical
and histochemical staining, animal identity and cohort
affiliation were blinded for the investigators. To obtain a
high level of comparability, every incubated or stained
section was evaluated by an experienced investigator for
quality of tissue and staining. Instances of deficient stain-
ing of tissue sections were excluded from further analysis.
(i) Quantification of viral tissue load: To quantify the
viral load in the cerebellar tissues, up to two non-
neighboring SIV glycoprotein GP41 (gp41)-stained
sections per macaque were analyzed. All SIV gp41+
cells were counted and related to the section area.
To determine the section area, images of the sec-
tions were obtained and analyzed with ImageJ soft-
ware (NIH, Bethesda, MD, USA). Multinucleated
giant cells (MNGC) were counted as one cell.
(ii)Analysis of anti-IBA-1 staining: To quantify micro-
glial/macrophage responses, two to three ionized
calcium-binding adapter molecule 1 (IBA-1)-
stained cerebellar sections per macaque were given
a neuroinflammatory activity score, based on
microglial activity (distinguished by cell shape,
ramified vs. amoeboid) and number of SIV-
encephalitis hallmarks (MNGC, microglial nod-
ules) per section. Further information regarding
the neuroinflammatory activity score is provided
in Additional file 1: Table S1.
(iii)Analysis of anti-CD68 staining: To quantify CD68+
cells, six images randomly chosen were taken at a
×400 magnification from up to three non-
neighboring anti-CD68-stained sections for each
Table 1 Infection status, treatment regime, and clinical status at






Control 44 No No No
50 No No No
69 No No No
87 No No No
88 No No No
SIV/-AIDS 75 Yes No No
80 Yes No No
85 Yes No No
92 Yes No No
93 Yes No No
SIV/+AIDS 71 Yes Yes No
74 Yes Yes No
78 Yes Yes No
79 Yes Yes No
82 Yes Yes No
86 Yes Yes No
SIV/+AIDS/+6-Cl-ddG 70 Yes Yes Yes
72 Yes Yes Yes
73 Yes Yes Yes
76 Yes Yes Yes
77 Yes Yes Yes
83 Yes Yes Yes
89 Yes Yes Yesc
91 Yes Yes Yes
aClinical manifestation of acquired immunodeficiency syndrome
bAdministration of 2,3-ddl (10 mg/kg s. c. daily) for 3 weeks, following 6-Cl-ddG
(75 mg/kg s. c. daily) for 6 weeks
cSole administration of 6-Cl-ddG (75 mg/kg s. c. daily) for 3 weeks
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macaque. ImageJ cell counter plug-in was used to
determine the number of CD68+ cells in each
image. The location of CD68+ cells was considered
by distinguishing between perivascular and paren-
chymal localizations. Perivascular localization was
defined as association to Virchow-Robin spaces
and parenchymal localization without any associ-
ation to vessels. Cells located in the pial meninges
were not considered for counting. MNGC counted
as one cell.
(iv)Analysis of anti-CD163 staining: To quantify
CD163+ cells, up to three non-neighboring CD163-
stained sections per macaque were analyzed.
Distinguishing between intravascular, perivascular,
and parenchymal localization, all CD163+ cells per
section were counted. Intravascular localization
was defined as an endothelial-attached cell, perivascu-
lar localization as associated to Virchow-Robin space,
and parenchymal localization without any association
to vessels. Cells located in the pial meninges were not
considered for counting. MNGC counted as one cell.
The determined number of cells was related to the
section area.
(v)Analysis of anti-albumin staining: Up to three non-
neighboring albumin-stained sections per macaque
were semi-quantitatively analyzed with respect to
the extravascular presence of albumin.
(vi)Determination of linear Purkinje cell density: To
determine the linear Purkinje cell (PC) density,
cerebellar tissue sections were Giemsa stained as
described above. Seven to ten images of cerebellar
cortical areas were randomly taken in ×100
magnification out of three non-neighboring sections
for each macaque. From the images taken per
animal, six were randomly chosen and analyzed
using ImageJ. For measurement of the PC layer
length, a freehand line through the center of the
PC bodies was drawn and the PC bodies were
counted. The data were captured and summed for
each macaque.
(vii)Determination of granule cell density: To
determine the density of granule cells (GC),
cerebellar tissue sections were Giemsa stained as
described. Six images of the GC layer areas were
randomly taken in ×400 magnification out of two
non-neighboring sections for each macaque. The
ImageJ cell counter plug-in was used to determine
the number of GC in each image. Only GC with
identifiable nuclei were counted. The resulting
number of GC was related to the pictured area of
the GC layer. Non-corresponding areas, such as
truncated vessels of neighboring cortical layers,
were subtracted. Data were captured and summed
for each macaque.
Statistical analysis
Statistical analysis was done using the GraphPad Prism 5.0
(GraphPad Software, La Jolla, USA) performing one-way
ANOVA and Bonferroni’s post-test for multiple compari-
sons to evaluate statistical differences between the groups.
A value of p < 0.05 was considered significant.
Results
Viral load, innate immunity signatures, astrogliosis, and
blood brain barrier (BBB) integrity were monitored by
analyzing cerebellar tissue sections of non-infected con-
trol macaques (control), SIV-infected macaques without
AIDS (SIV/-AIDS), and SIV-infected macaques exhibit-
ing AIDS (SIV/+AIDS). An additional group consisted of
macaques with symptoms of AIDS, subsequently treated
with CNS-permeant antiretroviral therapy (SIV/+AIDS/
+6-Cl-ddG).
Viral load and innate inflammatory signatures in the
rhesus macaque cerebellum in early- and late-stage lenti-
viral infection and effects of antiretroviral treatment with
6-Cl-ddG
The SIV viral load was determined by immunohisto-
chemistry for SIV gp41 on the cerebellar tissue sections
of the rhesus macaques in each experimental group. SIV
gp41+ cells were detected only in macaques with AIDS,
and not in uninfected control or asymptomatic SIV-
infected macaques (Fig. 1a, e, i, m, Fig. 2a). Antiretro-
viral treatment with 6-Cl-ddG reversed the SIV burden in
the cerebellum. Double-staining analysis revealed that SIV
gp41 was expressed in IBA-1+ cells, a general marker of
cells of monocytic/microglial origin (Additional file 1:
Figure S1), but not in astrocytes or neurons.
Using several phenotype markers, we determined the
innate immune signature in the cerebellum of ma-
caques during SIV infection and antiretroviral therapy.
In comparison to uninfected control macaques, a sig-
nificant numerical increase of microglia occurred in the
cerebellum in the early stage of SIV infection (SIV/-
AIDS) as detected with IBA-1. In the late stage of the
disease (SIV/+AIDS), signs of SIV-induced inflammation,
namely ameboid macrophages, mononuclear nodular infil-
trates, and multinucleated giant cells (MNGC), were ob-
served by IBA-1 immunostaining (Fig. 1i, j, k, l, Fig. 2b).
The microglial/macrophage activation markers CD68
and CD163 were occasionally immunodetected in the
cerebellum of the control and SIV/-AIDS macaques.
Their expression was upregulated in SIV/+AIDS (prefer-
entially in nodule- and giant cell-forming macrophages)
(Fig. 1k, l, Fig. 2c, d). CD68+ cells were mostly located in
the parenchyma whereas CD163+ cells were more vessel
associated. CD68 expression in this condition likely
reflects an M1 macrophage population, whereas CD163
indicates an M2 macrophage phenotype that is thought
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to represent the trafficking macrophages from the per-
iphery to the brain [34–36].
Antiretroviral treatment with 6-Cl-ddG prevented the
appearance of mononuclear infiltrates, mononuclear
nodules, and MNGC as detected with IBA-1 and CD68
in SIV/+AIDS (Fig. 1j, k, n, o, Fig. 2b, c). The number of
CD163+ cells was also reduced by 6-Cl-ddG but was still
increased in comparison to control and SIV/-AIDS group
(Fig. 1d, h, l, p, Fig. 2d).
Astroglial reactions in the cerebellum of the rhesus
macaques during lentiviral infection and effects of
antiretroviral treatment with 6-Cl-ddG
Bergmann glia, which are specialized astroglial cells essen-
tial for developmental granule cell migration, and posi-
tioned with their cell bodies in the vicinity of Purkinje
neurons, exhibited increased glial fibrillary acidic protein
(GFAP) expression in their processes in the molecular
layer in SIV/+AIDS as compared to control macaques
(Fig. 3f). Similarly, the astrocytes of the subcortical white
matter were also activated and showed upregulated GFAP
expression in SIV/+AIDS (Fig. 3d). Both the gliosis of
Bergmann glia and cerebellar white matter astrocytes were
significantly reduced compared to the SIV/+AIDS group
and near to control levels by 6-Cl-ddG (Fig. 3g–i, Fig. 4).
Perturbation of macromolecular integrity of the BBB in
the cerebellum of the rhesus macaques during lentiviral
infection and effects of antiretroviral treatment with 6-
Cl-ddG
In inflammatory foci with mononuclear nodules in the
subcortical cerebellar white matter, GFAP+ astrocytes
were reduced in SIV/+AIDS (Fig. 3d, e, Fig. 5f). In con-
trast, an increased expression of GFAP in the special
astroglial type, the cerebellar Bergmann glia, was detected
(Fig. 3f, Fig. 4). Double staining of GFAP with albumin
demonstrated that in these foci with reduced GFAP+
areas, albumin was accumulated in the parenchyma, sug-
gesting focally restricted macromolecular leakage of the
BBB (Fig. 5f). Staining of the adjacent sections for IBA-1
and SIV gp41 revealed that, in the areas with disintegrity
of the BBB, SIV-induced mononuclear nodules, infiltrates,
and giant cells occurred (Additional file 1: Figure S2).
Antiretroviral treatment with 6-Cl-ddG abolished the viral
cerebellar load and the associated productive inflamma-
tion, and preserved the macromolecular integrity of the
Fig. 1 Neuroinflammation. Representative slices stained for SIV gp41 (a–d), IBA-1 (e–h), CD68 (i–l), and CD163 (m–p). Note the extensive
neuroinflammation in the SIV/+AIDS group (c, g, k, o) compared to the Control and SIV/-AIDS groups. SIV+ cells are only detectable in the
SIV/+AIDS group. Antiretroviral treatment with 6-Cl-ddG lowers the degree of neuroinflammation, but not to base level (d, h, l, p). Scale bar
(in a) 100 μm in a–p, 15 μm in insets
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BBB, as monitored by immunohistochemistry for albumin
(Fig. 5g, h).
Neurodegeneration in the cerebellum of the rhesus
macaques during lentiviral infection and effects of
antiretroviral treatment with 6-Cl-ddG
The number of granule cells (Giemsa staining) was found
to be significantly reduced in SIV/-AIDS as compared to
the control (Fig. 6b, d, f, h, Fig. 7a), whereas the linear
density of Purkinje neurons was not different from the
control in SIV/-AIDS (Fig. 6a, c, e, g, Fig. 7b). In the
symptomatic stage, the number of granule cells as well as
the linear Purkinje cell density was decreased (Fig. 6e, f,
Fig. 7). Antiretroviral treatment with 6-Cl-ddG did not re-
verse the loss of granule cells or Purkinje neurons in SIV/
+AIDS (Fig. 6g, h, Fig. 7).
Fig. 2 Quantification of SIV gp41+ (a), CD68+ (c), and CD163+ (d) cells and neuroinflammatory activity score (b). SIV gp41+ cells were detected
only in the cerebellum of the SIV/+AIDS group (8.23 ± 2.16/mm2) (a). This correlates with a high score in neuroinflammatory activity (4.83 ± 1.33)
(b). 6-Cl-ddG significantly reduces neuroinflammation (0.67 ± 0.82), but not to base level as seen in the control group (0 ± 0). A subliminal neuroin-
flammatory activity remains, like in the SIV/-AIDS group (1 ± 0). The number of CD68+ cells is significantly increased in the SIV/+AIDS group (259.5
± 53.7/mm2) compared to the control group (56.6 ± 16.2/mm2) and the SIV/-AIDS group (110.5 ± 35.4/mm2) (c). 6-Cl-ddG significantly reduces
CD68+ cell count to base level (50.8 ± 20.1/mm2). CD68+ cells show a predominantly parenchymal location. The total number of CD163+ cells is
increased in the SIV/+AIDS group (943.6 ± 69.5/cm2) compared to the control group (38.4 ± 3.3/cm2) and the SIV/-AIDS group (80.0 ± 53.5/cm2). 6-
Cl-ddG reduces significantly the total number of CD163+ cells (374.3 ± 12.5/cm2), but the number of intravascular and perivascular CD163+ cells is
constantly high (33.1 ± 4.9 vs. 28.9 ± 8/cm2). Illustration of mean values (MV) and standard deviation (SD) (MV ± SD). **p value <0.01, ***p
value <0.001
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Discussion
In the present study, we demonstrate that SIV infection
in rhesus macaques causes early neuronal loss of cere-
bellar granule cells in an asymptomatic stage of disease,
characterized by the absence of productive cerebellar
infection and neuroinflammatory signs, and late loss of
Purkinje cells, correlated with overt infection and in-
flammation in the cerebellum.
Vulnerability and resilience of cerebellar neurons in the
asymptomatic stage of disease without productive SIV
infection
One of the key findings in our study is the significant
loss of granule cells as an early event preceding the on-
set of either clinical signs of SIV disease, marked neuro-
inflammation, or productive CNS infection. Although
early invasion of human CNS by HIV, and primate CNS
by SIV, has been reported, CNS inflammation and viral
replication appear to be largely absent in the pre-AIDS
stage [37, 38]. Previous studies from our own laborator-
ies have demonstrated that neither viral protein nor viral
RNA is easily detectable in the non-lymphoid tissues of
SIV-infected but asymptomatic macaques [39], com-
pared to later stages of the disease. Bell et al. likewise
showed the apparent absence of HIV in the brain in hu-
man pre-AIDS cases [40]. Although viral replication in
the cerebellum was undetectable in the asymptomatic
stage of infection in our study, discrete signs of neuroin-
flammation, i. e., low-grade microglial and astroglial
activation, were seen in the cerebellum during this stage.
As the spleen and other lymphoid tissues represent the
major reservoir and sites of viral replication in T-
lymphocytes and monocytes in asymptomatic animals
[41], it is reasonable to assume that early viral effects in
the brain are initiated peripherally. Mechanisms for
such effects might include the production and release
of pro-inflammatory cytokines, in particular tumor necrosis
Fig. 3 Astrogliosis and Bergmann gliosis. Representative slices stained for GFAP. Note the extensive astrogliosis and Bergmann gliosis in the SIV/
+AIDS group (d–f) with focal rarefication of astroglial structures (e). The inset in e shows a hypertrophic astrocyte. g–i showing a molecular layer.
Note the distinct hypertrophy of Bergmann glia in the SIV/+AIDS group (f). 6-Cl-ddG treatment reduces astrogliotic reactions in white matter and
molecular layer (g–i), but not to base level as seen in the control group (a–c). Scale bar (in a) 500 μm in a, d, g; 62.5 μm in b, c, e, f, h, i; 20 μm
in insets. ML molecular layer, PL Purkinje layer, GL granular layer, WM white matter
Fig. 4 Quantification of GFAP+ area of molecular layer. There is a
significant increase in GFAP expression in the SIV/+AIDS group
(25.24 ± 3.37 %) compared to the control group (10.43 ± 2.55 %).
6-Cl-ddG reduces GFAP expression near to base level as seen in
the control group (12.24 ± 1.93 %). Illustration of mean values
(MV) and standard deviation (SD) (MV ± SD). ***p < 0.001
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factor alpha (TNF-α) and interleukin 1 (IL-1), from
activated peripheral immune cells, leading to the activa-
tion of brain-resident microglia and macrophages and
the augmentation of brain parenchymal levels of pro-
inflammatory cyto- and chemokines [42–45].
In addition, the release of viral proteins in the periphery,
with penetrance to CNS, is suspected to impair brain
neuronal survival. Crucial roles for the envelope protein
glycoprotein GP120 (gp120) and the trans-activator of
transcription protein (tat) in this process have been pro-
posed. Both viral proteins can cross the functional BBB
and appear at potentially neurotoxic concentrations in
the brain parenchyma [46–48]. Like TNF-α and IL-1,
the viral proteins gp120 and tat may exert their neuro-
toxicity via activation of glutamate (e. g., NMDA) re-
ceptors [45, 49–51], leading to dysregulation of calcium
homeostasis, overactivation of calcium-dependent sig-
nalling pathways, and subsequent neurotoxicity [52].
Purkinje cells, unlike granule cells, were resistant to
destruction in the early stages of SIV disease. A potential
factor in the relative resistance of Purkinje cells is their ex-
pression of calbindin, a cytosolic calcium-binding protein,
which may protect them, at least temporarily, from the
fatal consequences of NMDA-receptor overactivation.
Consistent with this hypothesis, Mattson et al. showed an
increased resistance of calbindin-expressing neurons, rela-
tive to calbindin-negative neurons, against calcium influx-
induced neurotoxicity in culture [53]. Ultimately, however,
Purkinje cell loss does occur in late-stage SIV disease. A
previous study provided evidence for possible Purkinje
cell damage in HIV encephalitis by demonstrating the
disruption of neurofilament signatures in distinct cere-
bellar Purkinje cell populations [21]. Excitotoxicity plays a
central role also in other neurodegenerative diseases, not-
ably Parkinson’s and Alzheimer’s diseases, and calbindin-
expressing neurons seem to be relatively resistant under
these conditions [54–56]. Given the relative resistance
of calbindin-expressing cells in these diseases, the ef-
fects of viral proteins, and virus-induced cytokines and
chemokines, may play a specific role in the loss of
Purkinje cells in lentiviral encephalitis, compared to
these other progressive neurodegenerative diseases. The
suspected mechanisms of cerebellar neurodegeneration
in the asymptomatic disease stage are illustrated in
Fig. 8a.
Persistence of neurodegeneration in the symptomatic
stage of disease with productive SIV infection in the
cerebellum
With progression to AIDS, the recognized SIV-
encephalitis characteristics can be observed in the cere-
bellum, according to the early findings of Lackner et al.
[57]. High inflammatory and viral load presents in high
numbers of productively infected monocytic cells
(gp41). High levels of inflammation are seen in strong
microglial and monocytic cell activation (CD68, IBA-1,
CD163), gliosis of astrocytic cell population (Bergmann
gliosis and astrogliosis), and breakdown of the BBB, as
demonstrated in the present study. These overt neu-
roinflammatory events in the cerebellum are most likely
to enhance progression of the already-existing granule
cell loss, and override the intrinsic calbindin-dependent
resilience of the Purkinje cells, resulting ultimately to a
significant loss in both cell populations. The presumed
multifactorial neuroinflammatory factors of neurode-
generation in the symptomatic stage are illustrated in
Fig. 8b.
In contrast to the early beginning and progressive
loss of cerebellar neurons demonstrated here, our
previous studies in the telencephalon of SIV-infected
Fig. 5 Breakdown of BBB. Representative slices of single (albumin, a,
c, e, g) and double (albumin/GFAP, b, d, f, h) stainings. Note the
extensive accumulation of albumin in the parenchyma of the SIV/
+AIDS group (e) as surrogate for breakdown of the BBB. BBB
breakdown correlates with a rarefication of astroglial structures (f).
Extravascular albumin is undetectable in the other groups. Scale bar
(in a) 500 μm in a, c, e, g; 62.5 μm in b, d, f, h. ML molecular layer,
PL Purkinje layer, GL granular layer, WM white matter
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Fig. 6 Neurodegeneration. Representative slices of Purkinje layer (a, c, e, g) and granular layer (b, d, f, h) with Giemsa staining. Arrows indicate
Purkinje cell bodies. Scale bar (in a) 100 μm in a, c, e, g; 50 μm in b, d, f, h
Fig. 7 Quantification of neuronal loss. a Significant reduction of granule cells (GC) in the SIV/-AIDS group (28,387 ± 1042/mm2) and extension in
the SIV/+AIDS group (849.9 ± 57.5/0.035 mm2) compared to the control group (35,269 ± 1584/mm2). 6-Cl-ddG stops the loss of granule cells, but
as expected cannot reverse it (24,821 ± 1966/mm2). b Significant decrease in the linear Purkinje cell density (LPD) in the SIV/+AIDS group (10.07 ±
1.31/mm) compared to the control group (14.93 ± 1.27/mm) and the SIV/-AIDS group (14.69 ± 0.52/mm). 6-Cl-ddG stops, but as expected cannot
reverse the reduction in the LPD (10.06 ± 1.19/mm). Illustration of mean value (MV) and standard deviation (SD) (MV ± SD)
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rhesus macaque brain revealed lentivirus-induced
neurochemical damage including reduced density of
projections of cholinergic basal forebrain neurons to
the frontal, parietal, and hippocampal-entorhinal cortex
but without changes in the number of these projection
neurons [33]. In contrast, degeneration of neocortical
large pyramidal neurons and of distinct neuronal popu-
lations of the basal ganglia in addition to synaptoden-
dritic damage has been demonstrated [19, 58–62].
Besides these previously recognized neurochemical and
neurostructural changes in neocortical areas and basal
ganglia, the neuroinflammation-related loss of granule
cells and Purkinje cells as shown in the present study is
a new finding and may represent an additional nexus
for the development of distinct HIV-related motor and
cognitive impairments. The occurrence of distinct be-
havioral impairments has been already demonstrated in
a previous study of rhesus macaques infected with the
same macrophage tropic SIV strain deltaB670 as used
in the present study [63].
One important aim of our study was to establish
whether or not decreasing viral load by treatment with
brain-permeant antiretroviral therapy late in the disease
process would affect neurodegeneration and when in
fact neurodegeneration was likely to occur within the
larger context of lentiviral disease progression. An im-
portant logical extension of the work reported here
would be earlier treatment with brain-permeant ART
and its effects on both neuropathology and behavioral
impairments (see Ref. [63]) in SIV disease, as a prelude
Fig. 8 Schematic diagram summarizing the pathophysiological scenarios in the cerebellum in the course of SIV infection and antiretroviral
treatment. While productive viral replication is undetectable, low-grade microglial activation is seen in the asymptomatic stage of disease (SIV/-
AIDS group, subfigure a): tat and gp120 are depicted as presumptive contributors to this process, and granule cell loss is depicted as the result of
the collective effects of microglial activation and SIV protein. In the symptomatic stage of disease (SIV/+AIDS group, subfigure b), productive
infection is paralleled by high-grade microglial activation, astrogliosis, and macromolecular defects of the BBB resulting in a further loss of
granule cells and onset of loss of Purkinje cells. Antiretroviral treatment with the highly CNS-permeant substance 6-Cl-ddG (SIV/+AIDS/+6-Cl-
ddG, subfigure c) results in clearance of productive viral infection and restoration of the disintegrated BBB but persistence of low-grade
microglial activation and losses of granule cells and Purkinje cells. MNGC multinucleated giant cells, BBB blood brain barrier
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to consideration of brain-permeant ART as an important
adjunct to HAART regimens currently in use in treat-
ment of human HIV disease.
To the best of our knowledge, a significant loss of
cerebellar granule cells associated with lentiviral infec-
tions has only been shown in cell culture [49, 64]. Apart
from case reports, Purkinje cell loss in this context has
not been systematically investigated yet [65, 66]. Damage
to Purkinje cells plays an important role in the patho-
physiology of other neurological disorders affecting the
cerebellum like essential tremor or spinocerebellar
ataxia [67–69]. Likewise, a significant loss of cerebellar
granule and Purkinje cells in Alzheimer’s disease seems
to correlate with an advanced stage of disease [70]. Re-
cently, a strong association of distinct and circumscribed
cerebellar atrophy with frontotemporal dementia and
Alzheimer’s disease and an involvement of the cerebellum
in Parkinson’s disease has been shown [71, 72]. Our re-
sults support these observations, suggesting that the cere-
bellum may be an important albeit as-yet unrecognized
brain participant in dementia and cognitive dysfunction
associated with major neurodegenerative diseases. As
numerous behavioral studies have indicated that the SIV
model resembles the neurobehavioral aspects of HIV
disease in HIV-infected patients [73], further attention to
cerebellar neuropathology and dysfunction may be war-
ranted in investigations of the CNS aspects of human HIV
infection and chronic disease.
The impact of brain-permeant antiretroviral therapy
In concordance to our previous results and the findings
of Fujii et al., the highly lipophilic antiretroviral drug 6-
Cl-ddG was found to effectively inhibit SIV replication
in the cerebellum [32, 74]. Although 6-Cl-ddG signifi-
cantly reduced the brain viral load and consecutively
eliminated productive SIV infection in the cerebellum, a
low-grade microglial/macrophage activation is persistent
as indicated by the constantly high number of perivascu-
lar CD163+ cells. This suggests an increased trafficking
of immune cells from the periphery into the brain and
possibly a switch in the polarization of macrophage
phenotypes to an anti-inflammatory subtype of macro-
phages. Ongoing persistent neuroinflammation under
ART recently revealed by modern in vivo PET technique
is in good accordance with our histopathological findings
and has been shown to correlate with poorer executive
performance [75]. The consequences of antiretroviral
therapy are illustrated in Fig. 8c.
Conclusions
We provide evidence that in SIV infection of the rhesus
macaque, neuronal cell loss in the cerebellum precedes
high viral load and peak levels of inflammation and
continues as the viral load and inflammation increases
during progression to AIDS. Treatment with a brain-
permeant antiretroviral during the symptomatic stage of
viral disease is highly effective, and prompt, to reduce the
viral load concomitantly with the inflammatory load. How-
ever, and as expected, severe neuronal loss is not reversed
by this treatment, suggesting that only early initiation of
brain-permeant antiretroviral therapy is likely to prevent
neuronal loss in the cerebellum and elsewhere in the brain.
The present results, insofar as the SIV-infected rhesus ma-
caque is an informative model for human HIV infection,
support current guidelines to initiate antiretroviral therapy
soon after evidence of infection, and independently of
peripheral signs and symptoms of disease progression,
including CD4+ cell loss and increasing intensity of viral
load. In fact, our results suggest that with respect to early
granule cell loss, brain-permeant antiretroviral treatment
can be avoided altogether, provided that ART is initiated
sufficiently early in the course of the disease to prevent the
entry of neurotoxic protein products of peripheral infection
into the brain.
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